China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary Xiangzhong Pharmaceutical received marketing approval from the National Medical Products Administration for its brexpiprazole active pharmaceutical ingredient.
The ingredient is used for schizophrenia in adults, according to a Tuesday filing with the Shanghai bourse.
Double-Crane's investment in the product reached 9.7 million yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.